Regeneron’s antibody cocktail is a combination of two monoclonal antibody therapies, casirivimab and imdevimab, which are thought to work by mimicking and stimulating the body’s natural immune system in order to help fight off the infection.
The FDA did not authorize this treatment for use among hospitalized patients or those who require supplemental oxygen. But the antibody cocktail is administered via an I.V., so it’s not likely that people will be able to access it outside of medical offices. This combination of therapies was shown to be helpful in a randomized, double-blind, placebo-controlled trial involving 799 nonhospitalized patients with mild to moderate COVID-19, according to the. Of those patients, 266 received a placebo within three days of getting their positive coronavirus test result. The others received one of two doses of the antibody cocktail.
Out of all the patients who received the antibody cocktail and were at a high risk for severe COVID-19 complications, only 3% required hospitalization or visited emergency room within 28 days of treatment. That’s compared to 9% of high-risk people in the placebo group who needed hospitalization or visited the emergency room within 28 days of receiving the placebo.
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Regeneron's antibody cocktail effective in preventing Covid-19, company saysThe antibody cocktail is authorized by the FDA as a treatment for patients diagnosed with Covid-19.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: CNN - 🏆 4. / 95 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »
Source: CNN - 🏆 4. / 95 Read more »
Source: POPSUGAR Fitness - 🏆 401. / 53 Read more »